Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
企業コードDARE
会社名Dare Bioscience Inc
上場日Apr 10, 2014
最高経営責任者「CEO」Johnson (Sabrina Martucci)
従業員数21
証券種類Ordinary Share
決算期末Apr 10
本社所在地3655 Nobel Dr Ste 260
都市SAN DIEGO
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号92122-1050
電話番号18589267655
ウェブサイトhttps://www.darebioscience.com/
企業コードDARE
上場日Apr 10, 2014
最高経営責任者「CEO」Johnson (Sabrina Martucci)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし